In this phase 2b , double-blind , placebo-controlled study , treatment-naive adults with genotype 1 ( n = 213 ) or 4 ( n = 25 ) were randomly assigned ( 3:1 ) to asunaprevir 200mg or placebo twice daily plus PegIFN/RBV .